T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-11-06: Form 8-K; Period of report 2020-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-10-23: Form 8-K; Period of report 2020-10-19; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2020-09-30: Form 8-K; Period of report 2020-09-25; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2020-08-17: Form 8-K; Period of report 2020-08-11; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-11-06 | 8-K | 2020-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2020 and held a conference call to discuss those results. | d23789d8k.htm |
| 2020-10-23 | 8-K | 2020-10-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d94602d8k.htm |
| 2020-09-30 | 8-K | 2020-09-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d948957d8k.htm |
| 2020-08-17 | 8-K | 2020-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2020 and held a conference call to discuss those results. | d86553d8k.htm |
| 2020-08-07 | 8-K | 2020-08-06 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 (a) The Annual Meeting of Stockholders of T2 Biosystems, Inc. (the “Company”) occurred on August 6, 2020. | d44260d8k.htm |
| 2020-07-14 | 8-K | 2020-06-30 | 8.01 Other Events | 8.01 On June 30, 2020, T2 Bioystems, Inc. (the “Company”) announced the US launch of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel, after validation of the test meeting the United States Food and Drug Administration’s (FDA’s) requirements for an Emergency Use Authorization (EUA). | d80666d8k.htm |
| 2020-06-30 | 8-K | 2020-06-30 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On June 30, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing preliminary estimated financial results for its fiscal quarter ending June 30, 2020. 7.01 On June 30, 2020, the Company issued a press release announcing the completion of validation and the US launch of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel. 8.01 • Estimated second quarter total revenue is expected to be in the range of $2.4 million to $2.6 million, compared to $1.8 million in the prior year period. | d98452d8k.htm |
| 2020-06-17 | 8-K | 2020-06-16 | 8.01 Other Events | 8.01 As previously reported, on April 7, 2020, T2 Biosystems, Inc. (the “Company”) received written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it was not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of the Company’s common stock being below $1.00 per share for 30 consecutive business days. | d878860d8k.htm |
| 2020-06-15 | 8-K | 2020-06-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 12, 2020, each of Michael Cima, Adrian Jones and Stanley Lapidus tendered resignations to T2 Biosystems, Inc. (the “Company”) stating that they resigned, effective immediately, from their positions as directors of the Company and all committees of the Board of Directors of the Company (the “Board”) on which they were serving. | d111258d8k.htm |
| 2020-05-22 | 8-K | 2020-05-22 | 8.01 Other Events | 8.01 As previously disclosed, T2 Biosystems, Inc. (the “Company”) is currently developing a SARS-CoV-2 test, (the “T2SARS-CoV-2 Test”), to run on the Company’s proprietary T2Dx Instrument platform and anticipates shipping the first tests to U.S. customers for clinical use as early as the end of June. | d935640d8k.htm |
| 2020-05-08 | 8-K | 2020-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2020 and held a conference call to discuss those results. | d927773d8k.htm |
| 2020-04-08 | 8-K | 2020-04-07 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 On April 7, 2020, the Company delivered written notice to Lincoln Park Capital Fund, LLC (“Lincoln Park”) terminating the Purchase Agreement between the Company and Lincoln Park dated as of July 29, 2019 (the “Purchase Agreement”). 3.01 On April 7, 2020, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). 8.01 On February 24, 2020, the Company communicated its three corporate priorities: accelerating sales, improving cost structure, and advancing new product pipeline. | d904700d8k.htm |
| 2020-03-25 | 8-K | 2020-03-24 | 8.01 Other Events | 8.01 • Estimated first quarter 2020 total revenue is expected to be in the range of $2.2 million to $2.6 million, compared to $1.8 million in total revenue the first quarter of 2019. | d894473d8k.htm |
| 2020-03-25 | 8-K | 2020-03-24 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On March 24, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing preliminary estimated financial results for its fiscal quarter ending March 31, 2020. 7.01 On March 24, 2020, the Company issued a press release announcing its entrance into a license agreement with the Center of Discovery and Innovation at Hackensack Meridian Health (the “Center”) pursuant to which the Company has licensed the right to adapt the Center’s COVID-19 test to run on the Company’s T2Dx® Instrument. | d903601d8k.htm |
| 2020-03-10 | 8-K | 2020-03-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 9, 2020, T2 Biosystems, Inc. (the “Company”) entered into Amendment No. 1 to Equity Distribution Agreement (“Amendment 1”) with Canaccord Genuity LLC (“Canaccord”), amending the Equity Distribution Agreement dated as of July 30, 2019, between the Company and Canaccord (the “Original Agreement” and, together with Amendment No. 1, the “Equity Distribution Agreement”). | d830480d8k.htm |
| 2020-02-27 | 8-K | 2020-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and year ended December 31, 2019 and held a conference call to discuss those results. | d865709d8k.htm |
| 2020-01-09 | 8-K | 2020-01-09 | 2.02 Results of Operations and Financial Condition | 2.02 On January 9, 2020, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and year ended December 31, 2019. | d861770d8k.htm |
| 2020-01-09 | 8-K | 2020-01-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously disclosed on Form 8-K filed with the Securities and Exchange Commission on July 30, 2019, (the “July 2019 Form 8-K”) on July 25, 2019, John McDonough notified T2 Biosystems, Inc. (the “Company”) of his resignation as President and Chief Executive Officer (“CEO”) of the Company, effective as of the date on which his successor commences employment with the Company or such earlier date as determined by the Board of Directors of the Company (the “Board”). | d861964d8k.htm |